Firibastat or Ramipril After Acute Myocardial Infarction for Prevention of Left Ventricular Dysfunction
Status:
Recruiting
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double-blind, active-controlled, dose-titrating phase 2
study to evaluate the safety and efficacy of firibastat administered orally BID (2 daily
doses) versus ramipril administered orally BID over 12 weeks after acute anterior MI.
Subjects will be followed for 12 weeks (over 4 study visits). A total of 294 male and female
subjects with a diagnosis of first acute anterior MI will be randomized. The subjects will
need to have a primary percutaneous coronary intervention (PCI) of the index MI related
artery within 24 hours after MI.